Scandion Oncology CEO Newsletter (March 2020)
Dear Scandion Oncology shareholder, Scandion Oncology wants to thank you for your continued trust and confidence in us and our work as we work through these challenging times together, and we hope that you and your families are safe and healthy. With the widening spread of COVID-19 across the world, we wanted to provide you with the latest updates on our activities, and, just as important, emphasize our continued commitment to bringing our drugs to the many cancer patients with untreatable drug resistant cancer disease.Clinical Phase II colorectal cancer study with SCO-101 to continue as